CareDx Q2 revenue beats estimates; outlook lifted
CDNA•Outlook raised for 2026
CareDx raised its 2026 revenue guidance to $490 million-$500 million from $447 million-$465 million. The company also lifted its 2026 adjusted EBITDA forecast to $66 million-$78 million from $43 million-$57 million.
CareDx said future results will exclude the Lab Products segment after its divestiture.
Drivers of revenue growth
Testing Services growth was driven by ongoing adoption of molecular surveillance testing, favorable reimbursement, and increased testing activity across transplant programs.
Patient and Digital Solutions revenue rose due to continued growth in CareDx Pharmacy services and adoption of digital solutions for transplant monitoring.
CareDx recognized a full quarter of Lab Products revenue before divesting the segment at quarter end.
Analyst and valuation context
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell".
The average consensus recommendation for the biotechnology & medical research peer group is "buy".
Wall Street's median 12-month price target for CareDx Inc is $35.00, about 1.2% below its July 29 closing price of $35.41.
The stock recently traded at 37 times the next 12-month earnings vs. a P/E of 22 three months ago.
Quarterly results beat estimates
CareDx said second-quarter revenue rose 52% year over year, beating analyst expectations. Adjusted earnings per share for the quarter also beat analyst expectations.
